Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Testing a Novel Device to Improve Speech Sound Recognition in Preterm Infants Born at 32 to 35 Weeks
Researchers are evaluating a new medical device designed to improve speech sound differentiation in hospitalized preterm infants. These infants, born between 32 and 35 weeks gestation, are at high risk for developmental delays and poor language outcomes due to limited exposure to infant-directed parental speech in the NICU. The study aims to test whether infants receiving a learning intervention with contingent mothers voice triggered by their sucking show better brain responses to speech sounds compared to those hearing the same voice non-contingently. The study compares two groups one receives 20-minute sessions of non-contingent recorded mothers voice played passively through a speaker device twice daily, and the other receives contingent exposure where the mothers voice plays only when the infant sucks on a pacifier sensor meeting a pressure threshold. The device integrates a sensor into a disposable pacifier connected to a speaker that delivers the voice at safe volume levels, designed for use in NICUs and meeting infection control standards. The intervention lasts up to 20 sessions over 3 weeks. Participants will undergo brain activity measurements using EEG before and after the intervention to assess speech sound processing. The study also explores how NICU background noise and room type affect the interventions effectiveness. Monitoring includes stable physiological states during sessions with nurses or therapists present. The total participation time includes EEG tests and up to three weeks of intervention with follow-up assessments for brain responses.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effects of the non-nutritive sweetener sucralose on gut bacteria in people with inflammatory bowel disease IBD, focusing on those with Crohns disease CD as a starting point. The study compares individuals with CD to healthy people without IBD to understand how sucralose might change the gut microbiome. Participants will follow a two-phase schedule over at least 35 days. In the first 14 days, all non-nutritive sweeteners are removed from their diet. Then, for the next 21 days, they consume sucralose at a dose of 2 sachets per day, equivalent to 2.5 mg per kg of body weight daily, which is below the acceptable daily intake. Both Crohns patients and healthy controls will participate in this intervention. During the study, participants will complete one virtual visit and two in-person visits. Researchers will collect fecal, urine, and blood samples before and after each phase to analyze changes in the gut microbiome and inflammation markers. They will measure specific outcomes such as fecal microbiome composition, myeloperoxidase activity, calprotectin levels, Crohns Disease Activity Index, and C-reactive protein. This monitoring helps understand sucraloses impact over time.